Prosecution Insights
Last updated: October 04, 2026

Basilea Pharmaceutica International AG Allschwil

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Basilea Pharmaceutica International AG Allschwil maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. These actions are distributed among 3 distinct examiners, with each examiner handling a single pending matter. This structure indicates that the company's current prosecution efforts are spread across several individual reviewers. The presence of 3 pending office actions suggests a moderate level of activity within the USPTO for this portfolio.

The workload is situated within 2 distinct art units, indicating some technical overlap among the pending applications despite the involvement of multiple examiners. SEAMAN, D MARGARET M is identified as the busiest examiner, currently overseeing 1 pending office action. This structure shows that the 3 pending office actions are being reviewed by a diverse group of examiners across a limited number of art units. For the practitioner, this means that while the examiners are different, the technical standards of the 2 distinct art units will be a consistent factor in the prosecution of these 3 pending matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
1
Medium (33%)
1
Easy (33%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting only1 (33%)
Double-patenting + other1 (33%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
33% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SEAMAN, D MARGARET M 1 76.5% +8.0%
SHOWALTER, ALEXANDER KEITH 1 54.4% +26.3%
HERNANDEZ, JACKSON J 1 51.4% +45.0%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18483703 METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS SHOWALTER, ALEXANDER KEITH 34d

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18483703 METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS SHOWALTER, ALEXANDER KEITH 34d
18002012 COMPOUNDS AND METHODS FOR TREATING FUNGAL INFECTIONS HERNANDEZ, JACKSON J —

Top Art Units

Art UnitApps
1629 1
1627 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18905680 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS SEAMAN, D MARGARET M — §102DP Non-Final OA — Pending Oct 03, 2024
18483703 METHODS OF TREATING STAPHYLOCOCCUS AUREUS BACTEREMIA INFECTIONS SHOWALTER, ALEXANDER KEITH 1629 §102§103§112 Final Rejection 34d Pending Oct 10, 2023
18002012 COMPOUNDS AND METHODS FOR TREATING FUNGAL INFECTIONS HERNANDEZ, JACKSON J 1627 DP Final Rejection — Pending Dec 15, 2022

Managing Basilea Pharmaceutica International AG Allschwil's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month